Literature DB >> 28214865

Inhibition of TRPC6 Signal Pathway Alleviates Podocyte Injury Induced by TGF-β1.

Haiting Huang, Yanwu You, Xu Lin, Chunrong Tang, Xiangjun Gu, Meiying Huang, Youling Qin, Junhua Tan, Feifan Huang.   

Abstract

BACKGROUND/AIMS: Transforming growth factor beta 1 (TGF-β1) plays a critical role in the pathogenesis of glomerulosclerosis. The purpose of this study was to examine the effects of inhibition of transient receptor potential cation channel C6 (TRPC6) on podocyte injury induced by TGF-β1 via nephrin and desmin mechanisms.
METHODS: A rat model of nephropathy was first induced by intravenous injections of adriamycin to determine TRPC6 signal pathway engaged in glomerulosclerosis in vivo. Conditionally immortalized podocytes were cultured in vitro and they were divided into four groups: control; TGF-β1 treatment; TGF-β1 with TRPC6 knockdown and TGF-β1 without TRPC6 knockdown. Real time RT-PCR and Western blot analysis were employed to determine the mRNA and protein of expression of nephrin, desmin and caspase-9, respectively. Flow cytometry was used to examine the apoptotic rate of podocytes and DAPI fluorescent staining was used to determine apoptotic morphology.
RESULTS: In vivo experiment, adriamycin significantly upregulated the protein expression of TGF-β1, TRPC6, desmin and caspase-9, and decreased nephrin. Consistent with the latter results, in vitro experiment mRNA and protein expression of desmin and caspase-9 was increased in cultured TGF-β1-treated podocytes, whereas nephrin was declined as compared with the control group. Importantly, TRPC6 knockdown significantly attenuated the upregulated desmin and caspase-9, and alleviated impairment of nephrin induced by TGF-β1. Moreover, typical morphologic features were presented in apoptotic podocytes. The number of apoptotic podocytes was increased after exposure to TGF-β1 and this was alleviated after TRPC6 knockdown. TRPC6 knockdown also decreased an apoptosis rate of TGF-β1-treated podocytes. Note that negative TRPC6 transfection control failed to alter an increase of the apoptosis rate in TGF-β1-treated podocytes.
CONCLUSIONS: TGF-β1 induced by glomerulosclerosis impairs the protein expression of nephrin and amplifies the protein expression of desmin and caspase -9 via TRPC6 signal pathway. Inhibition of TRPC6 alleviates these changes in podocytes-treated with TGF-β1 and attenuated apoptosis of podocytes. Our data suggest that TRPC6 signal plays an important role in mediating TGF-β1-induced podocyte injury via nephrin, desmin and caspase-9. Results of the current study also indicate that blocking TRPC6 signal pathway has a protective effect on podocyte injury. Targeting one or more of these signaling molecules may present new opportunities for treatment and management of podocyte injury observed in glomerulosclerosis.
© 2017 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Caspase 9; Desmin; Nephrin; Podocytes; TGF-β1; TRPC6

Mesh:

Substances:

Year:  2017        PMID: 28214865     DOI: 10.1159/000455985

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  12 in total

Review 1.  Role of TRPC6 in Progression of Diabetic Kidney Disease.

Authors:  Alexander Staruschenko; Denisha Spires; Oleg Palygin
Journal:  Curr Hypertens Rep       Date:  2019-05-21       Impact factor: 5.369

2.  Proline-dependent and basophilic kinases phosphorylate human TRPC6 at serine 14 to control channel activity through increased membrane expression.

Authors:  Henning Hagmann; Nicole Mangold; Markus M Rinschen; Tim Koenig; Karl Kunzelmann; Bernhard Schermer; Thomas Benzing; Paul T Brinkkoetter
Journal:  FASEB J       Date:  2017-09-06       Impact factor: 5.191

3.  Catalpol alleviates adriamycin-induced nephropathy by activating the SIRT1 signalling pathway in vivo and in vitro.

Authors:  Jiangnan Zhang; Ran Bi; Qiang Meng; Changyuan Wang; Xiaokui Huo; Zhihao Liu; Chong Wang; Pengyuan Sun; Huijun Sun; Xiaodong Ma; Jingjing Wu; Kexin Liu
Journal:  Br J Pharmacol       Date:  2019-12-11       Impact factor: 8.739

4.  (Pro)renin receptor decoy peptide PRO20 protects against adriamycin-induced nephropathy by targeting the intrarenal renin-angiotensin system.

Authors:  Renfei Luo; Kevin Yang; Fei Wang; Chuanming Xu; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2020-08-31

5.  [Correlation between expressions of VEGF and TRPC6 and their roles in podocyte injury in rats with diabetic nephropathy].

Authors:  Xiao-Na Zhu; Yu-Huan Wang; Juan-Juan Wu; Peng Dong; Min Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-03-20

6.  Spleen-Kidney Supplementing Formula Alleviates Renal Fibrosis in Diabetic Rats via TGF-β1-miR-21-PTEN Signaling Pathway.

Authors:  Chunyu Tian; Ya Wang; Hong Chang; Ji'an Li; Xiaojin La
Journal:  Evid Based Complement Alternat Med       Date:  2018-12-06       Impact factor: 2.629

7.  The role of podocyte damage in the etiology of ischemia-reperfusion acute kidney injury and post-injury fibrosis.

Authors:  Yi Chen; Liyu Lin; Xuan Tao; Yankun Song; Jiong Cui; Jianxin Wan
Journal:  BMC Nephrol       Date:  2019-03-28       Impact factor: 2.388

8.  Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice.

Authors:  Vadim V Klimontov; Anton I Korbut; Iuliia S Taskaeva; Nataliya P Bgatova; Maksim V Dashkin; Nikolai B Orlov; Anna S Khotskina; Evgenii L Zavyalov; Thomas Klein
Journal:  World J Diabetes       Date:  2020-12-15

9.  Transforming growth factor-β1-induced podocyte injury is associated with increased microRNA-155 expression, enhanced inflammatory responses and MAPK pathway activation.

Authors:  Xintong Zheng; Qiuhong Zhong; Xu Lin; Xianjun Gu; Xiaoyan Ling; Zhao Liang; Qing Qin; Xiuri Du
Journal:  Exp Ther Med       Date:  2021-04-14       Impact factor: 2.447

10.  ATF4-dependent heme-oxygenase-1 attenuates diabetic nephropathy by inducing autophagy and inhibiting apoptosis in podocyte.

Authors:  Shizhu Yuan; Xudong Liang; Wenfang He; Mingzhu Liang; Juan Jin; Qiang He
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.